Business
Telo Genomics Announces Non-Brokered Private Placement of Convertible Debentures for up to $1,200,000
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN TH...
About this update from Telo Genomics Corp.
[{"type":"text","content":"Telo Genomics Announces Non-Brokered Private Placement of Convertible Debentures for up to $1,200,000THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESToronto, Ontario--(Newsfile Corp. - January 19, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the \"Company\" or \"Telo Genomics\") is pleased to announce a non-brokered private placement offering of secured convertible debentures (\"Debentures\") for gross proceeds of up to $1,200,000 (the \"Offering\"). The Company may pay finder's fees in connection with the Offering.The Debentures will bear interest at a rate of 15% per annum, compounded quarterly, and will mature 9 months after the closing date (the \"Maturity Date\"). The principal amount of the Debentures may, at the holder's election, at any time before the Maturity Date, be converted into common shares of the Company at a conversion price of $0.05 per common share. For every $100,000 of convertible debentures issued, Telo Genomics will issue 2 million Detachable Warrants (each, a \"Warrant\"). Each Warrant will be exercisable to acquire one common share at an exercise price of $0.08 per share for a period of 12 months from the closing date. The Company has no right to prepay the Debentures prior to the Maturity Date.The proceeds raised from the Offering are expected to be used for lab trials and general working capital. The Offering is subject to certain conditions, including but not limited to receipt of all necessary approvals from the TSX Venture Exchange.The Debentures, Warrants and any securities issuable upon conversion or exercise will be subject to a four month hold period in accordance with applicable Canadian securities laws.About Telo Genomics Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic ...